ROME Therapeutics explored the dark genome for drug discovery, focusing on LINE-1 inhibitors for autoimmune and neurodegenerative diseases before winding down.
Cosigns
Team
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Data current as of September 12, 2023
Leads
Participating Firms
Angels